Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Mar 19, 2009

IBA Pads Assay Development Services with Acquisition of Axela Technology

  • The Institute of Bioanalytics (IBA) has purchased Axela’s assay-development platform, dotLab. IBA thus expands its contract assay development business such that customers will now have access to single or multiplexed immunoassays.

    In addition to custom assay development, IBA is partnering with Axela to expand the menu of biomarker assays optimized for use with the dotLab platform and the soon-to-be available panelPlus Sensors. This technology is being designed to be able combine preconfigured assays with novel markers to enhance validation activities.

    Benefits of the dotLab System include extended dynamic range, simultaneous measurement of high- and low-abundance markers, and concurrent detection of secondary information such as binding partners, isotype, and avidity, according to the companies.



Related content

Be sure to take the GEN Poll

Cancer vs. Zika: What Worries You Most?

While Zika continues to garner a lot of news coverage, a Mayo Clinic survey reveals that Americans believe the country’s most significant healthcare challenge is cancer. Compared to other diseases, does the possibility of developing cancer worry you the most?

More »